RBF Symposium

Abstract Book_2003
TECHNICAL PROGRAM
Ramanbhai Foundation 1^st International Symposium "Current trends in Pharmaceutical sciences: Drug Discovery - Journey from Mouse to Man"
Day I: Thursday : 23^rd January, 2003
8.00 – 9.00 hr							Registration
9.00 – 9.15 hr							Inauguration
9.20 – 10.20 hr							Welcome Address - Towards new research initiatives Mr. Pankaj R. Patel, Chairman & Managing Director, Zydus Cadila Inaugural Address Chief-Guest
Session I: Medicinal Chemistry
10.20 hr.							Key-Note Address Role of PPAR’s in Metabolism and Cell Physiology Prof Walter Wahli, Institut de Biologie Animale, Université de Lausanne, Switzerland.
11.10 hr.							TEA BREAK
11.30 hr.							RXRs, PPARs and Metabolic Diseases Dr. Ranjan Mukherjee, Senior Research Investigator, Bristol-Myers Squibb Co., Wilmington, USA
12.15 hr.							Development of Medicines Concerning Renin-Angiotensin System at Sankyo Dr. Hiroaki Yanagisawa Director, Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd., Japan
13.00 – 14.00 hr							LUNCH BREAK
14.00 hr							A New Paradigm of Drug Discovery for the Twenty-First Century Dr. Peter Lawrence Bullock, Purdue Pharma LP, Ardsley, New York , USA
14.45 hr							The Control of Acid Secretion by Proton Pump Inhibitors – An Ongoing Success Story of Tailored Molecules Dr. Volker Figala Vice President; Preclinical Development, Altana Pharma AG Byk-Gulden, Germany
15.30 hr							Novel Synthetic Methods for Fluorine - Containing Molecules Prof. Tamejiro Hiyama Department of Chemistry, Kyoto University, Japan
16.15 hr - 17.15 hr							TEA BREAK and POSTER SESSION
17.15 hr							Drug-DNA interactions : Microcalorimetry and Spectroscopy Dr. C. Vijaya Kumar Professor of Chemistry, Physical and Biological Chemistry, University of Connecticut, USA
18.00 hr							Human Genome and DNA Technology Dr. Pradeep Kumar Srivastava CDRI, Lucknow, India
19.00 hr							Cultural Programme
20.00 hr							DINNER

Day II : Friday : 24^th January, 2003
Session II: Separation Technology
08.30 hr		The Use of Enantioselective Chromatography In Drug Discovery and Drug Development Professor Irving W. Wainer Director, Drug Discovery and Bioanalytical Chemistry Laboratory, Laboratory of Clinical Investigation, National Institute on Aging / National Institutes of Health, USA
09.15 hr		Chiral Resolution: Past, Present & Future Dr William John Lough Reader in Pharmaceutical Analysis, Institute of Pharmacy, Chemistry & Biomedical Sciences, University of Sunderland, UK.
10.00 hr		Capillary Electrophoresis, Chiral Separation in Pharmaceutical Analysis Dr. David Llyod Principal Scientist, Analytical R&D, Bristol Myers Squibb, Wilmington, USA
10.45 hr - 11.00 hr		TEA BREAK
11.00 hr		Preparative Chromatographic Separation of Enantiomers Dr. Eric R. Francotte Head Separation & Cold Metabolism, Novartis Pharma AG, Research Department, Central Technologies, Basel, Switzerland.

Session III: Pre-clinical / Clinical Development of NCE’s

11.45 hr		Trends in Pre-Clinical Research Dr. Oppel Greeff President, Quintiles Transnational Corp., USA
12.30 hr		Evolving Paradigms of Preclinical Drug Development Processes: Bridging the Gap Between Discovery and Clinical Development Dr Subrahmanyam Vangala Site Head, Preclinical Pharmacokinetics, Johnson and Johnson Pharmaceutical Research and Development, USA
13.15 hr -14.00 hr		LUNCH
14.00 hr		Clinical Trial Designs to Facilitate Pre-clinical to Clinical Transition in Drug Development Dr. Darrell R. Abernethy Chief, Laboratory of Clinical Investigation, National Institute on Aging/ National Institutes of Health, USA
14.45 hr		Optimising Drug Development in Phase I/IIa Prof. Dr. Monika Seibert-Grafe, Board Certified Anaesthesiologist and Clinical Pharmacologist, Head of Coordination Centre for Clinical Trials, University Hospital Heidelberg, Germany
15.30 hr		Project Management in Clinical Drug Development Dr. Heinz W. Radtke Executive Vice-President, Research and Development, Byk-Gulden, Altana Pharma, Germany
16.15 hr		TEA BREAK

Session IV: Patents, ICH Guidelines & Business Development

16.45 hr		International Harmonisation and Overview – ICH Dr. Fritz Erni Head Novartis Pharmanalytica SA, Locarno, Switzerland
17.30 hr		Implications of the Changing Patent Regime and Patent Litigations in Pharma Mr. S. Majumdar Patent Attorney, S. Majumdar & Company, Kolkata, India
18.15 hr		Flexibility in Partnering, Becoming a Preferred Partner Dr. Ravi Sodha Business Licensing and Development, Head, Scientific Evaluation, Novartis Pharma AG
19.00 hr		Concluding Session
19.20 – 21.00 hr		ZRC Anniversary Celebrations followed by Dinner